Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry

Linda Baughn, Zohar Sachs, Klara E. Noble-Orcutt, Amit Mitra, Brian G. Van Ness, Michael A. Linden

Research output: Contribution to journalArticle

6 Scopus citations


Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3–4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.

Original languageEnglish (US)
Pages (from-to)1931-1940
Number of pages10
JournalLeukemia and Lymphoma
Issue number8
StatePublished - Aug 3 2017



  • bortezomib
  • cytometry
  • drug resistance
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this